Production Capacity Integration + Energy Independence, Blue Sail Medical's Glove Business Turnaround Expected

Recently, Blue Sail Medical (002382.SZ) announced that two key acquisition transactions involving its subsidiary Shandong Blue Sail Health Technology Co., Ltd. (hereafter “Shandong Health Tech”) have been successfully completed. Not only did they acquire 100% equity in Zibo Blue Sail Health Tech Co., Ltd. and Zibo Blue Sail Protective Products Co., Ltd. (hereafter “Zibo Health Tech and Zibo Protective”), but they also secured an 80% stake in Zibo Hongda Thermal Power Co., Ltd. (hereafter “Hongda Thermal Power”). These two projects work together to achieve dual breakthroughs: integrating glove production capacity and compensating energy costs, injecting strong momentum into Blue Sail Medical’s core glove business turnaround, with performance resilience expected to continue.

According to the announcement, both acquisitions were facilitated by a $200 million capital increase from a Thai industrial investor, not using Blue Sail Medical’s own funds, alleviating the company’s cash flow pressure and enabling precise business layout upgrades. Specifically, Shandong Health Tech acquired 100% equity in Zibo Health Tech and Zibo Protective for 800 million yuan, with the core goal of revitalizing existing nitrile glove resources, transforming the industry supply-demand imbalance caused by “new capacity addition” into “integration of existing capacity” to improve operational efficiency, and significantly boosting the overall competitiveness and profitability of the nitrile glove business. After the transaction, Shandong Health Tech will centrally manage all of Blue Sail Medical’s nitrile glove resources, forming a total annual capacity of approximately 25 billion pairs across three major production bases. The unified management of health protection products will create synergies in equipment deployment, process optimization, and supply chain management, with operational efficiency expected to continue improving.

Alongside capacity integration, addressing energy shortages has become another key breakthrough. Shandong Health Tech acquired an 80% stake in Hongda Thermal Power for 400 million yuan, primarily to systematically address the energy supply shortfall at Zibo’s nitrile glove production base and build an independent, controllable energy security system. As the only heat source center in its park, it can provide stable, low-cost electricity and heat to Blue Sail’s own glove factories. Additionally, thanks to the capital increase from Thailand, Shandong Health Tech obtained a rare combined heat and power (CHP) approval, with related units expected to start operation in Q2 2026, utilizing excess heat from glove production for power generation and grid sales. These positive factors enable the company to implement CHP in both Zibo and Weifang, further expanding cost advantages. The ongoing growth of the glove business will bring additional profit growth points for Blue Sail Medical.

By Q4 2025, the company’s glove business gross profit margin has successfully turned positive, and it is expected that the health protection segment will be the most significant driver of performance recovery in 2026. Currently, the nitrile glove capacity is operating at full production and sales, while exports of PVC gloves have surged significantly since October 2025, laying a solid foundation for price increases in these two major glove categories.

Amid multiple positive factors, the turnaround of Blue Sail Medical’s glove business is becoming increasingly clear. Currently, under the influence of global geopolitical factors, the prices of core raw materials for gloves have risen sharply, entering a cycle of price increases. Meanwhile, the company’s precise anticipation of raw material price trends, through strategic phased procurement and price locking, has essentially locked raw material costs through the first half of 2026, successfully avoiding cost pressures from this round of raw material price surges.

Furthermore, the company has two unique advantages in raw material security. First, its controlling shareholder’s chemical division is a leading enterprise in plasticizers and rosin resins nationwide, with annual revenue exceeding 10 billion yuan, and is a major supplier of raw materials for PVC gloves. Second, its Thai industrial investor owns over 200,000 tons of nitrile latex capacity; in extreme market situations, the company can source reasonably priced, stable nitrile latex from them.

Historical experience shows that the final price of gloves usually increases more than raw material prices, especially in the current industry cleanup and return of pricing power to leading companies, making price hikes more transmissible downstream. The company is expected to leverage its raw material cost-locking advantage to fully benefit from industry-wide price increases, achieving higher profit margins and rapid profit recovery.

Meanwhile, the company’s glove production line upgrades are progressing in phases. The Weifang plant completed its upgrade upon the first Thai investment in 2024, reaching advanced standards; by the end of 2025, both Zibo bases will have completed upgrades, significantly improving production efficiency and cost control. By acquiring thermal power plants to reduce energy costs and upgrading production lines to enhance operational efficiency, combined with the release of integration benefits and industry recovery opportunities, there remains considerable room for gross profit margin improvement in the glove business. Blue Sail Medical is poised for an unexpected performance elasticity boost.